Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy

Publication Data

• Title Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy
• Alternative Title Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer afte
• Author National Institute for Health and Clinical Excellence
• Publisher National Institute for Health and Clinical Excellence
• Publication date 2012
• Publication location Manchester
• Language English

Descriptive Notes

Issued: January 2012.
"This guidance updates and replaces NICE technology appraisal 150 (published in June 2008)"--Page 3.

Topics

• Colon (Anatomy) :: Cancer :: Chemotherapy :: England
• Colon (Anatomy) :: Cancer :: Chemotherapy :: Wales
• Rectum :: Cancer :: Chemotherapy :: England
• Rectum :: Cancer :: Chemotherapy :: Wales
• Monoclonal antibodies

Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy by National Institute for Health and Clinical Excellence. Published by National Institute for Health and Clinical Excellence in 2012. Publication and catalogue information, links to buy online and reader comments.